Ann: Investor Update, page-150

This is a complete generalisation that does not summarise the PainChek management team at all. I’m not sure on your angle and why you spend so much time here, but you would find that they have shown they very efficiently reach milestones. FDA was the exception, through the processes of the FDA, not PainChek.

I do not disagree that uptake has been slower than expected and cash burn could become an issue. I think in general you have made some completely invalid points on the company which have been untrue and off the mark. Please at least read back through the company announcements and let’s get back on track with some constructive discussion!